In conclusion, the results of the study showed that in patients with HER-2 negative, unresectable advanced or recurrent GC/GEJC chemotherapy combined with ICIs could greatly prolong PFS, but OS was not significantly improved, and AEs were manageable. The gene discussed is ERBB2; the disease is gastric cancer.